Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease

Frontiers in Pharmacology(2021)10.3389/fphar.2020.598910Source: DataRank Database

Epidermal Growth Factor Receptor: A Potential Therapeutic Target for Diabetic Kidney Disease is a research paper published in Frontiers in Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 4.17)OA: goldTopics (28)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

George Bayliss ORCID,Shougang Zhuang ORCID,Lili Sheng ORCID

Live enrichment

PubMed:33574751 PMC:PMC7870700 OpenAlex:https://openalex.org/W3125584116

National Natural Science Foundation of China

Grant: 81670623 81830021

NIDDK NIH HHS

Grant: R01 DK113256

National Institutes of Health

Grant: 1R01DK113256-01A1

Role of Histone Methyltransferase EZH2 in Acute and Chronic Renal Injury

National Institutes of Health

FWCI

4.17

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fphar.2020.598910/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fphar.2020.598910/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fphar.2020.598910/full

journalhttps://doi.org/10.3389/fphar.2020.598910

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33574751

Fields of Study

Diabetes Treatment and ManagementChronic Lymphocytic Leukemia ResearchMetabolism, Diabetes, and Cancer0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

MedicineEpidermal growth factor receptorDiseaseKidney diseasePathogenesisKidneyEGFR inhibitorsTherapeutic approachBioinformaticsCancer researchInternal medicineOncologyPharmacologyReceptorBiologyInflammationDiabetic nephropathyMetabolic DisturbanceHemodynamic AlternationMulticellular DysfunctionTherapeutics. PharmacologyRM1-950

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Urinary exosome proteins PAK6 and EGFR as noninvasive diagnostic biomarkers of diabetic nephropathy

10.6084/m9.figshare.24240161.v1figshare

Additional file 1 of Urinary exosome proteins PAK6 and EGFR as noninvasive diagnostic biomarkers of diabetic nephropathy

10.6084/m9.figshare.24240161figshare

Additional file 2 of Urinary exosome proteins PAK6 and EGFR as noninvasive diagnostic biomarkers of diabetic nephropathy

10.6084/m9.figshare.24240273.v1figshare

Additional file 2 of Urinary exosome proteins PAK6 and EGFR as noninvasive diagnostic biomarkers of diabetic nephropathy

10.6084/m9.figshare.24240273figshare

Additional file 3 of Urinary exosome proteins PAK6 and EGFR as noninvasive diagnostic biomarkers of diabetic nephropathy

10.6084/m9.figshare.26622502.v1figshare